Solid state solutions provider Holodiag and fine chemical R&D provider Holochem join forces.
Holodiag, provider of solid state solutions, and Holochem, provider of chemical and process development services, have signed a strategic partnership, enabling both companies to supply customers with a full range of integrated fine chemical and API contract development and manufacturing services through all stages of the drug development lifecycle.
CRO Holodiag is known for its expertise in pharmaceutical solid state. Over the past years, the company has increasingly focussed on R&D, and the new partnership with Holochem is in line with this strategic direction. Holochem’s areas of expertise is in the chemical, process and analytical development phases of key intermediates and APIs.
Holodiag and Holochem support their pharmaceutical customers with fully integrated EP/USP/ICH compliant drug development and IMPD/IND/DMP regulatory support throughout the entire development process. Services remain available on a stand-alone basis. The partnership is also facilitated by the close geographic proximity of the companies, both based in Val-de-Reuil, one hour west of Paris, France.
Holodiag and Holochem will jointly exhibit at CPhI Worldwide (Oct. 24–26, 2017, Frankfurt).
Source: Holochem, Booth 41D50
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.